These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 18833422)

  • 1. Cataract occurrence in patients treated with antipsychotic drugs.
    Souza VB; Moura Filho FJ; Souza FG; Rocha CF; Furtado FA; Gonçalves TB; Vasconcelos KF
    Braz J Psychiatry; 2008 Sep; 30(3):222-6. PubMed ID: 18833422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kerato-lenticular ocular deposits and visual impairment with prolonged chlorpromazine use: A case series.
    Gowda GS; Hegde A; Shanbhag V; Narayanaswamy JC; Jaisoorya TS
    Asian J Psychiatr; 2017 Feb; 25():188-190. PubMed ID: 28262147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cataract occurrence with antipsychotic drugs.
    Shahzad S; Suleman MI; Shahab H; Mazour I; Kaur A; Rudzinskiy P; Lippmann S
    Psychosomatics; 2002; 43(5):354-9. PubMed ID: 12297603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are schizophrenia or antipsychotic drugs a risk factor for cataracts?
    Ruigómez A; García Rodríguez LA; Dev VJ; Arellano F; Raniwala J
    Epidemiology; 2000 Nov; 11(6):620-3. PubMed ID: 11055620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular abnormalities in chronic schizophrenia: clinical implications.
    Smith D; Pantelis C; McGrath J; Tangas C; Copolov D
    Aust N Z J Psychiatry; 1997 Apr; 31(2):252-6. PubMed ID: 9140633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrimeprazine-induced corneal deposits and cataract revealed by urine drug profiling test.
    Kim ST; Koh JW; Kim JM; Kim WY; Choi GJ
    J Korean Med Sci; 2010 Nov; 25(11):1688-91. PubMed ID: 21060765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Face-to-face questionnaire survey on the use of multiple antipsychotics and the manifestation of side effects in outpatients with schizophrenia].
    Hirosawa I; Ogino M; Mano Y; Tajima M; Ohuchi K; Kato Y; Kotaki H; Asahi M; Yamada H
    Yakugaku Zasshi; 2011; 131(11):1605-11. PubMed ID: 22041699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of atypical antipsychotics and risks of cataract development in patients with schizophrenia: A population-based, nested case-control study.
    Chou PH; Chu CS; Lin CH; Cheng C; Chen YH; Lan TH; Huang MW
    Schizophr Res; 2016 Jul; 174(1-3):137-143. PubMed ID: 27061658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraocular pressure in schizophrenic patients treated with psychiatric medications.
    Souza VB; Moura Filho FJ; Souza FG; Pereira Filho SA; Coelho SS; Furtado FA; Gonçalves TB; Vasconcelos KF
    Arq Bras Oftalmol; 2008; 71(5):660-4. PubMed ID: 19039459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund.
    Weinbrenner S; Assion HJ; Stargardt T; Busse R; Juckel G; Gericke CA
    Pharmacopsychiatry; 2009 Mar; 42(2):66-71. PubMed ID: 19308881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials.
    Khan A; Schwartz K; Stern C; Redding N; Kolts RL; Brown WA; Robinson DS
    J Clin Psychiatry; 2007 Dec; 68(12):1828-33. PubMed ID: 18162012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of neuroleptic-induced movement disorders: an 8-year follow-up study in chronic schizophrenia inpatients.
    Parksepp M; Ljubajev Ü; Täht K; Janno S
    Nord J Psychiatry; 2016 Oct; 70(7):498-502. PubMed ID: 27093226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmaco-epidemiological study on antipsychotic drug prescription in French Psychiatry: Patient characteristics, antipsychotic treatment, and care management for schizophrenia].
    Brunot A; Lachaux B; Sontag H; Casadebaig F; Philippe A; Rouillon F; Cléry-Melin P; Hergueta T; Llorca PM; Moreaudefarges T; Guillon P; Lebrun T
    Encephale; 2002; 28(2):129-38. PubMed ID: 11972139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical antipsychotics in first admission schizophrenia: medication continuation and outcomes.
    Mojtabai R; Lavelle J; Gibson PJ; Bromet EJ
    Schizophr Bull; 2003; 29(3):519-30. PubMed ID: 14609245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraoperative floppy-iris syndrome associated with use of antipsychotic drugs.
    Matsuo M; Sano I; Ikeda Y; Fujihara E; Tanito M
    Can J Ophthalmol; 2016 Aug; 51(4):294-296. PubMed ID: 27521670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsychotic safety and efficacy concerns.
    Meyer JM
    J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of DSM-5 changes on the diagnosis and acute treatment of schizophrenia.
    Mattila T; Koeter M; Wohlfarth T; Storosum J; van den Brink W; de Haan L; Derks E; Leufkens H; Denys D
    Schizophr Bull; 2015 May; 41(3):637-43. PubMed ID: 25528758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.